• bluebird bio, Inc. NASDAQ:BLUE is a leader in biotechnology, focusing on gene therapies for severe genetic conditions.
• The company conducted a 1-for-20 reverse stock split to comply with Nasdaq’s listing requirements.
• This strategic split aims to enhance its stock price and secure its NASDAQ listing, crucial for growth.

bluebird bio, Inc. (NASDAQ:BLUE) sits at the forefront of biotechnology, dedicated to tackling severe genetic diseases through groundbreaking gene therapies. Competing in a rapidly evolving market, the company aspires to transform patient lives with innovative treatments.

On December 13, 2024, bluebird bio implemented a 1-for-20 reverse stock split. This initiative received approval from the Board of Directors and stockholders during the annual meeting on December 4, 2024. The purpose of this reverse stock split is to elevate the per share market price, enabling bluebird to satisfy Nasdaq’s minimum bid price requirement for continuous listing.

The reverse stock split became effective at 5 p.m. Eastern Time on December 12, 2024, with trading commencing on a split-adjusted basis from December 13 under the same ticker symbol “BLUE”. The new CUSIP number for the common stock following the split is 09609G 209, ensuring its clear identification in market dealings.

Prior to the split, the stock traded at $0.38, which reflects a 2.96% decrease. Within the trading day, the stock price varied between $0.3719 and $0.41. Over the previous year, bluebird bio’s stock experienced highs of $3.58 and lows of $0.29, signaling notable volatility.

The company’s market cap is around $73.89 million, with a trading volume of 5,050,689 shares. This reverse stock split is pivotal for stabilizing its stock price and ensuring continued NASDAQ listing, key factors for the company’s growth and maintaining investor trust.